
The annual BHF conference is taking place in Cape Town from 14 -17 May 2023. Networking, collaboration and learning about emerging healthcare issues, innovation and industry action, and discussions regarding what’s next.
Recent Posts

FDA Approval Lumvoa Therapeutics Redefines Treatment Landscape for Thyroid Eye Disease
The FDA Approval Lumvoa Therapeutics delivers the first full insulin-like growth factor-1 receptor (IGF-1R) antagonist for thyroid eye disease (TED), a rare autoimmune condition that triggers orbital inflammation, proptosis, diplopia, pain, and risk of vision loss.

Public-Private Partnership Enhances HIV Treatment Access Through Innovative Drug Integration
A new agreement between Merck and the ADAP Crisis Task Force significantly advances HIV Treatment Access by integrating the newly approved single-tablet regimen IDVYNSO™ (doravirine/islatravir) into state AIDS Drug Assistance Programs that served more than 250,000 people with HIV in 2024.

Regulatory Insights from EMA CHMP Meeting Highlights
The EMA CHMP Meeting Highlights from 22-25 June 2026 show the committee advancing six new medicines while maintaining rigorous evidentiary standards for complex and rare conditions. Positive opinions covered an inactivated influenza vaccine for adults 50 and older, a levodopa-carbidopa intestinal...